GRAIL (NASDAQ:GRAL – Get Free Report) and Propanc Biopharma (OTCMKTS:PPCB – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.
Risk and Volatility
GRAIL has a beta of 4.52, suggesting that its share price is 352% more volatile than the S&P 500. Comparatively, Propanc Biopharma has a beta of 3.45, suggesting that its share price is 245% more volatile than the S&P 500.
Earnings & Valuation
This table compares GRAIL and Propanc Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| GRAIL | $141.83 million | 27.25 | -$2.03 billion | ($11.63) | -8.52 |
| Propanc Biopharma | N/A | N/A | -$1.82 million | ($45.12) | -0.01 |
Propanc Biopharma has lower revenue, but higher earnings than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and target prices for GRAIL and Propanc Biopharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| GRAIL | 1 | 1 | 2 | 0 | 2.25 |
| Propanc Biopharma | 0 | 0 | 0 | 0 | 0.00 |
GRAIL presently has a consensus target price of $97.50, suggesting a potential downside of 1.65%. Given GRAIL’s stronger consensus rating and higher possible upside, research analysts plainly believe GRAIL is more favorable than Propanc Biopharma.
Profitability
This table compares GRAIL and Propanc Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| GRAIL | -286.43% | -15.69% | -13.35% |
| Propanc Biopharma | N/A | -3,652.66% | -971.09% |
Summary
GRAIL beats Propanc Biopharma on 8 of the 11 factors compared between the two stocks.
About GRAIL
GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.
About Propanc Biopharma
Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.
Receive News & Ratings for GRAIL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRAIL and related companies with MarketBeat.com's FREE daily email newsletter.
